Establishing Muscle Impedance Parameters With Electrical Impedance Myography
| Status: | Recruiting |
|---|---|
| Conditions: | Infectious Disease, Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 46 - Any |
| Updated: | 3/2/2019 |
| Start Date: | June 19, 2018 |
| End Date: | October 2019 |
| Contact: | Joan Nye, BS |
| Email: | joan.nye@yale.edu |
| Phone: | (203) 737-7095 |
Application of Electrical Impedance Myography (EIM) to Establish Muscle Impedance Parameters as a Potential Biomarker of Inclusion Body Myositis (IBM)
The primary aim of this study is to assess the changes in the impedance parameters of muscles
in inclusion body myositis (IBM) through electrical impedance myography (EIM), an emerging
non-invasive electrodiagnostic technology. Muscle impedance parameters can potentially serve
as an objective biomarker reflecting disease progression and severity.
in inclusion body myositis (IBM) through electrical impedance myography (EIM), an emerging
non-invasive electrodiagnostic technology. Muscle impedance parameters can potentially serve
as an objective biomarker reflecting disease progression and severity.
In this pilot study, the electrical impedance myography (EIM) parameters of individuals with
inclusion body myositis (IBM) will be compared with age and sex matched normal data. Along
with EIM parameters, clinical outcome measures will be obtained to understand how EIM data
correlates with these parameters. A focused study to assess muscle health in IBM patients
through EIM is essential to gather further insight into the potential application of this
technology as a disease biomarker. Additionally, this investigation will provide critical
data for the design of a subsequent biomarker validation study.
inclusion body myositis (IBM) will be compared with age and sex matched normal data. Along
with EIM parameters, clinical outcome measures will be obtained to understand how EIM data
correlates with these parameters. A focused study to assess muscle health in IBM patients
through EIM is essential to gather further insight into the potential application of this
technology as a disease biomarker. Additionally, this investigation will provide critical
data for the design of a subsequent biomarker validation study.
Inclusion Criteria:
- Clinico-pathologically defined IBM in the absence of any other significant
neurological problem or cognitive dysfunction.
- Healthy controls will be age and gender-matched to the enrolled IBM patients.
Exclusion Criteria for both IBM and control group:
- Patients with decompensated congestive heart failure
- Patients with chronic kidney disease on hemodialysis
- Patients with active cancer on chemotherapy or radiotherapy
- Patients with severe disease who are already wheel-chair bound
We found this trial at
1
site
Click here to add this to my saved trials
